Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT01794520. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The Phase 1 primary objectives of this study were to assess the safety profile, characterize pharmacokinetics (PK) and determine the dosing schedule, maximum tolerated dose (MTD), and recommended Phase 2 dose (RPTD) of ABT-199 (venetoclax) when administered in participants with relapsed or refractory multiple myeloma. This study also assessed the safety profile and PK of venetoclax in combination with dexamethasone in participants with t(11;14)-positive multiple myeloma. The Phase 2 primary objective was to further evaluate the objective response rate (ORR) and very good partial response or better rate (VGPR+) in participants with t(11;14)-positive multiple myeloma.
Study identification
- NCT ID
- NCT01794520
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 117 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 9, 2012
- Primary completion
- Nov 28, 2021
- Completion
- Nov 28, 2021
- Last update posted
- Apr 9, 2023
2012 – 2021
United States locations
- U.S. sites
- 21
- U.S. states
- 19
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic - Scottsdale /ID# 75808 | Scottsdale | Arizona | 85259-5452 | — |
| University of Arkansas for Medical Sciences /ID# 170002 | Little Rock | Arkansas | 72205 | — |
| Yale University /ID# 203704 | New Haven | Connecticut | 06510 | — |
| Emory University, Winship Cancer Institute /ID# 74993 | Atlanta | Georgia | 30322 | — |
| Ingalls Memorial Hosp /ID# 205346 | Harvey | Illinois | 60426 | — |
| Tulane Cancer Center Clinic /ID# 204123 | New Orleans | Louisiana | 70112 | — |
| Tufts Medical Center /ID# 203814 | Boston | Massachusetts | 02111-1552 | — |
| University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 170007 | Ann Arbor | Michigan | 48109 | — |
| Mayo Clinic - Rochester /ID# 74994 | Rochester | Minnesota | 55905-0001 | — |
| Hattiesburg Clinic /ID# 201187 | Hattiesburg | Mississippi | 39401 | — |
| Washington University-School of Medicine /ID# 76094 | St Louis | Missouri | 63110 | — |
| University of Nebraska Medical Center /ID# 169158 | Omaha | Nebraska | 68198-6840 | — |
| The John Theurer Cancer /ID# 200248 | Hackensack | New Jersey | 07601 | — |
| Duke Cancer Center /ID# 129356 | Durham | North Carolina | 27710-3000 | — |
| University Hospitals - Seidman Cancer Center /ID# 204502 | Cleveland | Ohio | 44106-1716 | — |
| Ohio State Cancer Center /ID# 200249 | Columbus | Ohio | 43210 | — |
| Avera Cancer Institute /ID# 204178 | Sioux Falls | South Dakota | 57105 | — |
| Baylor University Medical Ctr. /ID# 170056 | Dallas | Texas | 75246 | — |
| Swedish Cancer Institute - Edmonds /ID# 170006 | Seattle | Washington | 98104 | — |
| Univ of Wisconsin Hosp/Clinics /ID# 200246 | Madison | Wisconsin | 53792-0001 | — |
| Medical College of Wisconsin /ID# 205229 | Milwaukee | Wisconsin | 53226-3522 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01794520, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 9, 2023 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01794520 live on ClinicalTrials.gov.